01—Abstract
Summary
Summary of the 10-K filed February 27, 2015. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories' 2014 10-K filing reveals a company undergoing significant strategic transformations.
A major development was the completed separation of its research-based pharmaceuticals business into AbbVie Inc. on January 1, 2013. More recently, the company announced the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc., which closed shortly after the reporting period. These strategic moves indicate a focus on streamlining operations and concentrating on core growth areas such as nutritional products, diagnostics, and vascular devices, with a significant emphasis on emerging markets.
The company also made several key acquisitions, including CFR Pharmaceuticals in Latin America and Veropharm in Russia, to bolster its presence in these growing regions. Despite ongoing pricing pressures and regulatory complexities inherent in the healthcare industry, Abbott demonstrated resilience, with sales growth driven by its nutritional and diagnostics segments.
02—Key points
Key Highlights
- Abbott completed the separation of its research-based proprietary pharmaceuticals business into AbbVie Inc. on January 1, 2013, creating two distinct publicly traded companies.
- The company announced the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. in July 2014, with the transaction closing shortly after the reporting period (February 27, 2015).
- Abbott made significant strategic acquisitions to expand its reach in emerging markets, including CFR Pharmaceuticals S.A. (Latin America) for approximately $2.9 billion and Veropharm (Russia) for approximately $315 million.
- The nutritional and diagnostics businesses were key drivers of sales growth and margin improvement over the last three years.
- Emerging markets represented nearly 50% of total company sales and experienced robust growth, with sales increasing 12.5% in 2014 and 10.8% in 2013, excluding foreign exchange impacts.
- The company's vascular business faced pricing pressures, particularly in drug-eluting stents, leading to flat sales in 2013 and 2014, though new product introductions and market penetration provided some growth.
- Abbott continued its commitment to returning capital to shareholders, increasing its quarterly dividend by 40% in 2014 and announcing share repurchase programs.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2014, Abbott Laboratories kept $0.11.
- Revenue$20.25B100.0%
- Cost of revenue−$9.22B45.5%
- Gross profit$11.03B54.5%
- Operating costs−$8.43B41.6%
- Operating income$2.60B12.8%
- Interest, other & tax−$315.0M1.6%
- Net income$2.28B11.3%
Where FY2014 revenue went
$20.25B- Cost of revenue: $9.22B, 46% of revenue
- SG&A: $6.53B, 32% of revenue
- Net income: $2.28B, 11% of revenue
- Other operating costs: $1.90B, 9.4% of revenue
- Interest, other & tax: $315.0M, 1.6% of revenue
Kept 11% as net incomeInterest, other & tax $315.0M · 1.6%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2014filed February 27, 2015Financial Statements
FY2014 against FY2013
| Line item | FY2014FY2013 | Change |
|---|---|---|
| Revenue | $20.25B$19.66B | +3.0% |
| Cost of Revenue | $9.22B$9.19B | +0.3% |
| Gross Profit | $11.03B$10.46B | +5.4% |
| SG&A Expenses | $6.53B$6.37B | +2.5% |
| Operating Expenses | $17.65B$17.52B | +0.7% |
| Operating Income | $2.60B$2.13B | +21.8% |
| Interest Expense | $150.00M$145.00M | +3.4% |
| Net Income | $2.28B$2.58B | −11.3% |
| EPS (Basic) | $1.50$1.64 | −8.5% |
| EPS (Diluted) | $1.49$1.62 | −8.0% |
| Shares Outstanding (Basic) | 1.52B1.56B | −2.7% |
| Shares Outstanding (Diluted) | 1.53B1.57B | −3.0% |
05—Questions
Frequently Asked Questions
What were the major strategic changes for Abbott Laboratories during the reporting period?
The most significant strategic move was the separation of its research-based proprietary pharmaceuticals business into AbbVie Inc. in early 2013. Additionally, Abbott announced and subsequently closed the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. shortly after the reporting period. The company also focused on expanding its presence in emerging markets through strategic acquisitions.
Which business segments showed the strongest performance?
The nutritional products and diagnostics businesses were the primary drivers of sales growth and margin improvement. These segments benefited from demographic trends, new product introductions, and efficiency initiatives.
What challenges did Abbott face in its vascular business?
The vascular business experienced pricing pressures, particularly in drug-eluting stents and other coronary products, which offset volume increases and led to flat sales in 2013 and 2014. The company also noted declines in market share in the U.S. for drug-eluting stents.
How is Abbott positioned in emerging markets?
Abbott has a strong and growing presence in emerging markets, which accounted for nearly 50% of total sales. The company made significant acquisitions in Latin America (CFR Pharmaceuticals) and Russia (Veropharm) to further enhance its position in these high-growth regions.
06—Continue